Drotrecogin Alfa (Activated) in Adults with Septic Shock
Top Cited Papers
- 31 May 2012
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 366 (22), 2055-2064
- https://doi.org/10.1056/nejmoa1202290
Abstract
There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients with septic shock.Keywords
This publication has 32 references indexed in Scilit:
- Statistical analysis plan of PROWESS SHOCK studyIntensive Care Medicine, 2010
- A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*Critical Care Medicine, 2010
- Comparison of Dopamine and Norepinephrine in the Treatment of ShockThe New England Journal of Medicine, 2010
- The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis*Critical Care Medicine, 2010
- Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shockIntensive Care Medicine, 2008
- Activated protein C (Xigris®) treatment in sepsis: a drug in troubleActa Anaesthesiologica Scandinavica, 2006
- Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulationJournal of Thrombosis and Haemostasis, 2004
- Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe SepsisSurgical Infections, 2004
- Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisCritical Care Medicine, 2003
- APACHE IICritical Care Medicine, 1985